Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec 6;2024(1):541-546.
doi: 10.1182/hematology.2024000578.

Pregnancy: MPN management before, during, and after pregnancy

Joan How  1 , Gabriela Hobbs  2
Affiliations
Review

Pregnancy: MPN management before, during, and after pregnancy

Joan How et al. Hematology Am Soc Hematol Educ Program. .

Abstract

The aging obstetric population, combined with more frequent myeloproliferative neoplasm (MPN) diagnoses in younger patients, will result in hematologic providers increasingly caring for MPN patients in pregnancy. There are special considerations that pertain to management of pregnancy in MPN patients. This includes increased risks of thrombosis and hemorrhage as well as pregnancy complications that are likely related to placental dysfunction associated with an MPN diagnosis, including preeclampsia, preterm delivery, and intrauterine growth restriction. Complicating these outcomes is the uncertainty of the safety of many commonly used drugs in MPNs in pregnancy and breastfeeding. Given the overall low incidence of pregnancy in MPNs, many guidelines are based on expert opinions and extrapolation from other high-risk pregnancy populations. In this case-based review, we summarize the literature on MPN pregnancy outcomes and synthesize recommendations to provide guidance on the antepartum and postpartum management of MPN patients. Special attention is also made to issues relevant to preconception, including fertility and the use of assisted reproductive technology.

PubMed Disclaimer

Conflict of interest statement

Joan How: no competing financial interests to declare.

Gabriela Hobbs: no competing financial interests to declare.

Figures

None
Graphical abstract
See this image and copyright information in PMC

References

    1. Srour SA, Devesa SS, Morton LM, et al.. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12. Br J Haematol. 2016;174(3):382-396. - PMC - PubMed
    1. Van Egeren D, Escabi J, Nguyen M, et al.. Reconstructing the lineage histories and differentiation trajectories of individual cancer cells in myeloproliferative neoplasms. Cell Stem Cell. 2021;28(3):514-523.e9. - PMC - PubMed
    1. Barbui T, Vannucchi AM, Buxhofer-Ausch V, et al.. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J. 2015;5(11):e369. - PMC - PubMed
    1. de Bastos M, Stegeman BH, Rosendaal FR, et al.. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev. 2014;2014(3):CD010813. - PMC - PubMed
    1. Middeldorp S, Nieuwlaat R, Baumann Kreuziger L, et al.. American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing. Blood Adv. 2023;7(22):7101-7138. - PMC - PubMed

LinkOut - more resources